DJ Shipley

A standard BUD/S class starts with over 200 candidates and finishes with fewer than 20 graduating.

"you start with 200-and-something people, you graduate less than 20. It's those are 200 of the most physically capable people of that year in the United States Navy and they couldn't make it." (said at 0:54:48)

While Basic Underwater Demolition/SEAL (BUD/S) training has one of the highest attrition rates among military qualification courses and starting class sizes can exceed 150–200 candidates, typical graduation rates are historically documented at approximately 20% to 25% (around 40–50 graduates from a class of 200). Claiming that a standard class of over 200 finishes with fewer than 20 graduates represents an attrition rate exceeding 90%, which exaggerates the average graduation rate, though individual classes or original (non-recycled/roll-in) cohort completion rates can occasionally dip that low.

• contradicts: Stress Fracture and Attrition in Basic Underwater Demolition SEAL Trainees (? 2005) · cited 4x in the literature

  "Two major but separate issues affect this program: stress fractures and attrition. Stress fracture rates are around 5-9% and may lead to attrition or training delays. Ultimately, only about 25% of trainees complete the program." (abstract, results, passage verified)

  openalex
• context: Psychological and physiological changes during basic, underwater, demolition/SEAL training (Physiology & Behavior 2022) · cited 5x in the literature

  "Data was collected at four timepoints throughout the assessment and selection course from 353 students over three classes." (abstract, results, passage verified)

  openalexfull study (doi)

Ibogaine eliminates substance addiction in a single administration.

"But you know, it kills addiction in one shot, which is crazy. People addicted to heroin—like I dipped Copenhagen for 17 years. Never wanted to quit. And I woke up the very next morning from ibogaine and I've never had a dip." (said at 2:45:57)

While open-label case series, observational studies, and preclinical models show that a single dose of ibogaine can acutely reduce opioid withdrawal symptoms and drug craving during detoxification, claiming that it 'kills addiction in one shot' vastly overstates the clinical evidence. Comprehensive reviews of the clinical literature emphasize that nearly all human data come from uncontrolled, open-label, or retrospective studies at high risk of bias, with no double-blind randomized controlled trials confirming long-term efficacy or cure for opioid use disorder. Relapse remains common, and ibogaine carries serious safety risks, particularly cardiotoxicity and fatal arrhythmias from QT prolongation.

• partial: Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abst… (Frontiers in pharmacology 2018) · cited 111x in the literature

  "We report here that ibogaine therapy administered in a safe dose range diminishes opioid withdrawal symptoms and reduces drug cravings. Pharmacological treatments for opioid dependence include detoxification, narcotic antagonists and long-term opioid maintenance therapy. Our results support product development of single oral dose administration of ibogaine for the treatment of opioid withdrawal during medically supervised detoxification to transition drug dependent individuals to abstinence." (abstract, results, passage verified)

  pubmedfull study (doi)
• context: Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Tre… (Molecules (Basel, Switzerland) 2026) · cited 1x in the literature

  "However, the clinical translation of ibogaine remains substantially constrained by fragmented and heterogeneous evidence, the absence of regulatory frameworks in several jurisdictions, limited phytochemical validation and standardization of available formulations, and unresolved concerns regarding cardiac safety." (abstract, results, passage verified)

  pubmedfull study (doi)
• contradicts: Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives. (Journal of clinical psychopharmacology 2026) · cited 1x in the literature

  "Most of the positive efficacy data come from uncontrolled, open-label, or retrospective studies, many conducted in nonclinical settings, with a high risk of bias. No double-blind RCT to date has demonstrated that ibogaine or noribogaine can effectively treat opioid use disorder (OUD)... Although observational data suggest that ibogaine may alleviate symptoms of OUD, PTSD, or polysubstance dependence, these findings remain exploratory. Moreover, serious ibogaine-related adverse events have been reported, especially cardiotoxicity due to QT prolongation, which represents a considerable risk given the currently unproven efficacy." (abstract, results, passage verified)

  pubmedfull study (doi)